Valuation
- Market cap
- 5,436,503,000
- Revenue TTM
- $0
- Net income TTM
- $-105,430,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 547,918
- Avg volume
- 892,720
- Day's range
- $79.43 – $82.95
- Shares out
- 66,210,000
- Stochastic %K
- 59%
- Beta
- -0.37
- Analysts
- Strong Sell
- Price target
- $145.21
Company profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phas...
Show more
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 606 7910
- Website
- https://orukatx.com
- Address
- 855 Oak Grove Avenue, Suite 100, Menlo Park, United States
Latest news
No headlines yet.
